NasdaqCM - Nasdaq Real Time Price USD

iCAD, Inc. (ICAD)

1.5400

-0.0500

(-3.14%)

At close: 4:00 PM EDT

1.5400

0.00

(0.00%)

After hours: 4:00 PM EDT

iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium

ProFound Cloud, powered by Google Cloud architecture and Google’s Health AI innovations, redefines accessibility to critical insights, empowering radiologists in early breast cancer detectionNew partnership with Densitas provides end-to-end breast health solution ensuring every aspect of a woman’s breast health journey is addressedEnhanced ProFound Detection Workstation features streamline mammogram interpretation for radiologists NASHUA, N.H., April 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASD

GlobeNewswire 8 days ago

ICAD
-3.14%
iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk evaluationExpands access to iCAD’s AI-powered ProFound Breast Health Suite and Densitas’ AI solutions to patients and medical professionals worldwide NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection so

GlobeNewswire 10 days ago

ICAD
-3.14%
iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

Study confirms iCAD’s Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammogramsNASHUA, N.H., April 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today that new data indicates its AI-powered solution effectively uncovers calcium deposits in the breast vessels, a sign of possible cardiovascular disease in wome

GlobeNewswire 11 days ago

ICAD
-3.14%
iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)

iCAD implements ProFound AI Detection to improve mammography reading and breast cancer detection in low-resource institutions and medically underserved communitiesNASHUA, N.H., April 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global health collaboration with RAD-AID International. RAD-AID, a non-profit charitable organization dedicated to improving radiology healthcare in

GlobeNewswire 16 days ago

ICAD
-3.14%
iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale

ProFound Cloud redefines accessibility to critical insights, empowering radiologists in early breast cancer detectionNASHUA, N.H., April 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of ProFound Cloud. The innovative Software-as-a-Service (SaaS) platform provides medical providers with a cost-effective, secure, and scalable means to access and deploy the latest ProFound Br

GlobeNewswire 17 days ago

ICAD
-3.14%
iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists

Newly released capabilities -- limiting the number of marks on a 3D view, color-coding lesion marks, and color-coding the ProFound Scorecard -- enhance radiologists' interpretability and efficiencyNASHUA, N.H., March 19, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced new, advanced workstation features for ProFound De

GlobeNewswire last month

ICAD
-3.14%
Artificial Intelligence, Real Profits: 3 Stocks to Outsmart the Market

The market is overlooking many stocks that could benefit from the proliferation of AI over the longer term. There are companies using AI to solve real-world problems, and others providing the raw materials that enable the AI boom to progress. We’re even seeing the undervaluing of companies whose chips enable AI to be produced and work its magic, or that build and run the data centers that host the processors that AI utilizes. With that said, here are three undervalued AI stocks for long-term inv

InvestorPlace last month

AVGO

ICAD
-3.14%
IRM
iCAD, Inc. (NASDAQ:ICAD) Q4 2023 Earnings Call Transcript

iCAD, Inc. (NASDAQ:ICAD) Q4 2023 Earnings Call Transcript March 12, 2024 iCAD, Inc. beats earnings expectations. Reported EPS is $0.05, expectations were $-0.05. iCAD, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to the iCAD Incorporated […]

Insider Monkey last month

ICAD
-3.14%
Q4 2023 ICAD Inc Earnings Call

Q4 2023 ICAD Inc Earnings Call

Thomson Reuters StreetEvents last month

ICAD
-3.14%
iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results

Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-yearFull-Year Operating Cash Flow ($5) million vs. ($12.8) million prior yearYear ending cash balance of $21.7M NASHUA, N.H., March 12, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, today announced results for its fiscal fourth quarter and full year ended D

GlobeNewswire last month

ICAD
-3.14%
Investors in iCAD (NASDAQ:ICAD) from three years ago are still down 87%, even after 44% gain this past week

Over the last month the iCAD, Inc. ( NASDAQ:ICAD ) has been much stronger than before, rebounding by 64%. But only the...

Simply Wall St. last month

ICAD
-3.14%
The Hot List: 3 AI Stocks Worth Buying on Weakness

Wall Street has correctly recognized that artificial intelligence (AI) is a game-changer. It enables individuals to use computers more easily than ever before to find the best answers to complex questions. Additionally, AI allows companies to become more productive and profitable by reducing their labor costs. This is because AI can perform some tasks once carried out by humans. However, Wall Street has mostly focused on buying into firms that sell the tools needed to produce or utilize AI. Furt

InvestorPlace last month

SDGR

ICAD
-3.14%
AI
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

Clinical evidence demonstrates ProFound Detection’s AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional false negatives Findings reveal substantially lower radiology reading workload Detection of Breast Arterial Calcification (BAC) by ProFound Heart Health could serve as biomarker to evaluate broader cardiovascular disease in women NASHUA, N.H., Feb. 28, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powere

GlobeNewswire last month

ICAD
-3.14%
iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

Dr. Hricak offers extensive experience in radiology, real-world application of AI-enabled imaging solutions, research, and global healthcare perspectivesNASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Dr. Hricak to its Board of Directors, effective immediately.

GlobeNewswire last month

ICAD
-3.14%
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year 2023 financials after the market close, and host a conference call at 4:30 PM Eastern Time on Tuesday, March 12, 2024. Earnings call details are as follows:Toll Fr

GlobeNewswire last month

ICAD
-3.14%
iCAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

NASHUA, N.H., Feb. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 12-14, 2024, in Snowbird, UT. Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief F

GlobeNewswire 2 months ago

ICAD
-3.14%
iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member

Mr. Doyle offers extensive experience in AI enabled healthcare platforms and global business strategy.NASHUA, N.H., Jan. 30, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Michael J. Doyle to its Board of Directors, effective immediately. Mr. Doyle is a seasoned technology and healthcare exec

GlobeNewswire 2 months ago

ICAD
-3.14%
iCAD Expands Executive Sales Leadership Team as Business Grows

Bill Keyes shifts and expands his role to Senior Vice President, Global Sales Operations and Peter Graham joins iCAD as Senior Vice President, North American Sales to accelerate growth while organization adds new products and partnerships.NASHUA, N.H., Dec. 18, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced the expansion of its sales leadership with the addition of Peter Graham, as Senior Vice Presi

GlobeNewswire 3 months ago

ICAD
-3.14%
Wealth Accumulation: 3 Stocks with Multibagger Potential

While it’s never easy to identify multibagger stocks, this may be one of the best times in decades to “swing for the fences” by buying undervalued growth names that are well-positioned to at least triple over the next few years. Amid excessive worries about interest rates, the Street has pushed down many unprofitable, high-potential companies’ stocks to absurdly low levels. Now that those fears are dissipating, these firms are well-positioned to make huge comebacks. Interest rates recently dropp

InvestorPlace 4 months ago

ICAD
-3.14%
BNGO
iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare

Key apps from the iCAD Breast Health Suite are now integrated with GE HealthCare’s new MyBreastAI Suite*AI applications streamline workflow and support clinicians in delivering more personalized breast care, including cancer detection, density assessment, and recommendations NASHUA, N.H., Nov. 28, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced that key artificial intelligence (AI) powered solutions

GlobeNewswire 4 months ago

ICAD
-3.14%

Performance Overview

Return	ICAD	S&P 500
YTD	-12.99%	+4.14%
1-Year	+7.69%	+19.55%
3-Year	-91.34%	+18.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

iCAD, Inc. (ICAD)

iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium

iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)

iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale

iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists

Artificial Intelligence, Real Profits: 3 Stocks to Outsmart the Market

iCAD, Inc. (NASDAQ:ICAD) Q4 2023 Earnings Call Transcript

Q4 2023 ICAD Inc Earnings Call

iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results

Investors in iCAD (NASDAQ:ICAD) from three years ago are still down 87%, even after 44% gain this past week

The Hot List: 3 AI Stocks Worth Buying on Weakness

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

iCAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member

iCAD Expands Executive Sales Leadership Team as Business Grows

Wealth Accumulation: 3 Stocks with Multibagger Potential

iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare

Performance Overview